Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neuro-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EPHA5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPHA5 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed by SDS-PAGE. |
View EPHA5 Products |
| Gene Delivery | EPHA5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Ideal for cell-based functional and conformation-dependent assays. |
View EPHA5 Products |
| Benchmark Ab | Anti-EPHA5 Recombinant Antibody Recombinant positive control derived from benchmark therapeutic sequences. High affinity, sequence verified. |
View EPHA5 Products |
| Validator | EPHA5 siRNA Set For target knockdown verification and target validation in phenotypic assays. |
View EPHA5 Products |
| Related Target A | EFNA5 Primary GPI-anchored ligand for EPHA5. Crucial for ligand-blocking assays and receptor-ligand interaction studies. |
View EFNA5 Products |
| Related Target B | EPHA2 Major oncogenic homolog in the Eph receptor family. Essential for counter-screening to ensure drug selectivity. |
View EPHA2 Products |
| Related Target C | EPHA3 Homologous Eph receptor. Key component for subfamily off-target profiling panels. |
View EPHA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus EPHA5 ortholog proteins available with >95% purity and verified sequences. |
| Subfamily counter-screening | Eph receptor family panels (including EPHA2, EPHA3, EPHA4) strictly verified by mass spectrometry and SDS-PAGE. |
| Lack of positive control antibodies | Clinical benchmark antibodies (biosimilars) included in our catalog as reference controls. |
| False positives in binding assays | Validated siRNA sets included to confirm specificity via gene knockdown in target cell lines. |
Live EPHA5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EPHA5 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and CAR-T cell therapies targeting solid tumors and neuro-oncology indications. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific conformation epitopes, pH-dependent internalization pathways, and overcoming resistance mechanisms in refractory cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Academic Institutes, Biopharma Startups | Non-Small Cell Lung Cancer (NSCLC), Glioblastoma | Internalization Assay (Requires high-purity, glycosylated EPHA5 ECD-Fc for binding kinetics) |
| CAR-T / Cell Therapy | Oncology Research Centers | Brain Tumors, Solid Tumors | Cell Line Construction (Requires Lentivirus for stable EPHA5 expression to screen effector functions) |
| Small Molecule Inhibitor | Kinase Inhibitor Developers | Refractory Cancers, Metastatic Disease | Selectivity Assay (Requires EPHA5 kinase domain mutants vs. WT and homolog panels) |